GREENBROOK TMS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.11 USD | +10.00% |
|
+20.88% | -59.33% |
| 30/05 | Madryn Asset Management Engages in Discussions with Greenbrook TMS | CI |
| 27/05 | Certain Warrants of Greenbrook TMS Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. | CI |
| Sales 2022 | 6.91Cr 576.41Cr | Sales 2023 | 7.38Cr 615.47Cr | Capitalization | 1.16Cr 97Cr |
|---|---|---|---|---|---|
| Net income 2022 | -6.1Cr -508.81Cr | Net income 2023 | -4.8Cr -400.38Cr | EV / Sales 2022 | 2.27 x |
| Net Debt 2022 | 11Cr 883.44Cr | Net Debt 2023 | 13Cr 1.06TCr | EV / Sales 2023 | 1.88 x |
| P/E ratio 2022 |
-0.73
x | P/E ratio 2023 |
-0.22
x | Employees | 508 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Greenbrook TMS Inc.
More press releases
| 1 day | +10.00% | ||
| 1 week | +20.88% | ||
| 1 month | +6.80% | ||
| 3 months | +139.13% | ||
| 6 months | -52.91% | ||
| Current year | -59.33% |
1 week
0.09
0.11
1 month
0.080.17
Current year
0.040.64
1 year
0.040.84
3 years
0.0413.89
5 years
0.0417.55
10 years
0.0417.55
| Managers | Title | Age | Since |
|---|---|---|---|
William Leonard
CEO | Chief Executive Officer | 59 | 09/18/09 |
Peter Willett
DFI | Director of Finance/CFO | 34 | 20/23/20 |
Iris Krug
CMP | Compliance Officer | - | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Elias Vamvakas
BRD | Director/Board Member | 65 | 09/18/09 |
William Leonard
CEO | Chief Executive Officer | 59 | 09/18/09 |
Frank Tworecke
BRD | Director/Board Member | 77 | 09/18/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 0.11 | +10.00% | 172,156 |
| 30/24/30 | 0.1 | -3.10% | 4,291 |
| 29/24/29 | 0.1032 | +12.17% | 5,468 |
| 28/24/28 | 0.092 | +1.10% | 98,936 |
| 24/24/24 | 0.091 | -1.09% | 2,941 |
Delayed Quote OTC Markets, May 01, 2024 at 01:22 am IST
More quotes
Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray) therapy in the United States for the treatment of depressive disorder (MDD) and other mental health disorders. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. The Company operates a network of outpatient mental health service centers that specialize in Treatment across the United States. It offers Treatment Centers in convenient locations to provide easy access to patients and clinicians. The Company owns and operates 133 Treatment Centers in the Commonwealths of Massachusetts, Virginia and Pennsylvania and the States of Maryland, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, and South Carolina.
Calendar
26/06/2024
- Annual General Meeting
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -59.33% | 51.26L | |
| -23.39% | 1.56TCr | |
| -2.70% | 1.17TCr | |
| +2.65% | 1.16TCr | |
| +2.37% | 1.01TCr | |
| -10.45% | 715.53Cr | |
| +8.05% | 684.58Cr | |
| -4.29% | 570.56Cr | |
| +13.33% | 429.78Cr | |
| -3.96% | 429.72Cr |
- Stock Market
- Equities
- GBNHF Stock
